Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice

Vaccine

Volumn 29, Issue 44, 2011, Pages 7631-7637

  Chauhan, Neelima B ^a,b   Davis, Francesca ^a,b   Xiao, Chun ^a,b  

^a JESSE BROWN VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alzheimer's disease; Anterograde axonal transport; Endocytic uptake; Intranasal passive immunization; Olfactory sensory neurons; Wheat germ agglutinin

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; EPITOPE; OLIGOMER; WHEAT GERM AGGLUTININ;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; IMMUNOTHERAPY; MALE; MOUSE; NERVE FIBER TRANSPORT; NONHUMAN; POLYMERIZATION; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES; BRAIN; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; WHEAT GERM AGGLUTININS;

EID: 80053596797     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.009     Document Type: Article

References (73)

1. Finder V.H. Alzheimer's disease: a general introduction and pathomechanism. J Alzheimers Dis 2010, 22(Suppl. 3):5-19.
2. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol 2009, 118(July (1)):5-36.
3. Eckert A., Schulz K.L., Rhein V., Gotz J. Convergence of amyloid-beta and tau pathologies on mitochondria in vivo. Mol Neurobiol 2010, 41(June (2-3)):107-114.
4. Huang H.C., Jiang Z.F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J Alzheimers Dis 2009, 16(1):15-27.
5. Imahori K. The biochemical study on the etiology of Alzheimer's disease. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86(1):54-61.
6. Maccioni R.B., Farias G., Morales I., Navarrete L. The revitalized tau hypothesis on Alzheimer's disease. Arch Med Res 2010, 41(April (3)):226-231.
7. Small S.A., Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 2008, 60(November (4)):534-542.
8. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci 2008, 31:175-193.
9. Chauhan N.B., Siegel G.J. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. Expert Rev Vaccines 2004, 3(December (6)):717-725.
10. Holtzman J.L. Amyloid-beta vaccination for Alzheimer's dementia. Lancet 2008, 372(October (9647)):1381. author reply - 2.
11. Lemere C.A., Maier M., Peng Y., Jiang L., Seabrook T.J. Novel Abeta immunogens: is shorter better?. Curr Alzheimer Res 2007, 4(September (4)):427-436.
12. McGeer P.L. Amyloid-beta vaccination for Alzheimer's dementia. Lancet 2008, 372(October (9647)):1381. author reply - 2.
13. Schenk D.B., Seubert P., Grundman M., Black R. A beta immunotherapy: lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis 2005, 2(5):255-260.
14. Wisniewski T., Konietzko U. Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol 2008, 7(September (9)):805-811.
15. Hanson L.R., Frey W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008, 9(Suppl. 3):S5.
16. Illum L. Nasal drug delivery - possibilities, problems and solutions. J Control Release 2003, 87(February (1-3)):187-198.
17. Minn A., Leclerc S., Heydel J.M., Minn A.L., Denizcot C., Cattarelli M., et al. Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier. J Drug Target 2002, 10(June (4)):285-296.
18. Turker S., Onur E., Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004, 26(June (3)):137-142.
19. Thorne R.G., Pronk G.J., Padmanabhan V., Frey W.H. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127(2):481-496.
20. Thorne R.G., Frey W.H. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 2001, 40(12):907-946.
21. Hanson L.R., Frey W.H. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J Neuroimmune Pharmacol 2007, 2(March (1)):81-86.
22. Gao X., Wu B., Zhang Q., Chen J., Zhu J., Zhang W., et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 2007, 121(August (3)):156-167.
23. Bourgeois C., Bour J.B., Aho L.S., Pothier P. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J Virol 1998, 72(January (1)):807-810.
24. Gigliotti F., Haidaris C.G., Wright T.W., Harmsen A.G. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun 2002, 70(March (3)):1069-1074.
25. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006, 27(June (18)):3482-3490.
26. Thorne R.G., Emory C.R., Ala T.A., Frey W.H. Quantitative analysis of the olfactory pathway for drug delivery to the brain. Brain Res 1995, 692(September (1-2)):278-282.
27. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 2006, 26(October (40)):10129-10140.
28. Chauhan N.B., Siegel G.J., Lichtor T. Distribution of intraventricularly administered antiamyloid-beta peptide (Abeta) antibody in the mouse brain. J Neurosci Res 2001, 66(October (2)):231-235.
29. Cerpa W., Dinamarca M.C., Inestrosa N.C. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr Alzheimer Res 2008, 5(June (3)):233-243.
30. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286(October (5440)):735-741.
31. Doerfler P., Shearman M.S., Perlmutter R.M. Presenilin-dependent gamma-secretase activity modulates thymocyte development. Proc Natl Acad Sci U S A 2001, 98(July (16)):9312-9317.
32. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001, 414(November (6860)):212-216.
33. Pakaski M., Kasa P. Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Curr Drug Targets CNS Neurol Disord 2003, 2(June (3)):163-171.
34. Hock C., Maddalena A., Raschig A., Muller-Spahn F., Eschweiler G., Hager K., et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer's disease. Amyloid 2003, 10(March (1)):1-6.
35. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003, 100(April (7)):4162-4167.
36. Eckman E.A., Watson M., Marlow L., Sambamurti K., Eckman C.B. Alzheimer's disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem 2003, 278(January (4)):2081-2084.
37. Tucker H.M., Kihiko M., Caldwell J.N., Wright S., Kawarabayashi T., Price D., et al. The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 2000, 20(June (11)):3937-3946.
38. Iwata N., Tsubuki S., Takaki Y., Shirotani K., Lu B., Gerard N.P., et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001, 292(May (5521)):1550-1552.
39. Bush A.I., Pettingell W.H., Multhaup G., d Paradis M., Vonsattel J.P., Gusella J.F., et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994, 265(September (5177)):1464-1467.
40. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30(June (3)):665-676.
41. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003, 60(December (12)):1685-1691.
42. Hamaguchi T., Ono K., Yamada M. Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. Cell Mol Life Sci 2006, 63(July (13)):1538-1552.
43. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002, 3(October (10)):824-828.
44. Hara H. [Abeta vaccine therapy for Alzheimer's disease]. Rinsho Shinkeigaku 2005, 45(November (11)):867-869.
45. Weiner H.L., Lemere C.A., Maron R., Spooner E.T., Grenfell T.J., Mori C., et al. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 2000, 48(October (4)):567-579.
46. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408(December (6815)):979-982.
47. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(December (6815)):982-985.
48. Das P., Murphy M.P., Younkin L.H., Younkin S.G., Golde T.E. Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 2001, 22(September-October (5)):721-727.
49. Sigurdsson E.M., Scholtzova H., Mehta P.D., Frangione B., Wisniewski T. Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 2001, 159(August (2)):439-447.
50. Frenkel D., Katz O., Solomon B. Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A 2000, 97(October (21)):11455-11459.
51. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000, 6(August (8)):916-919.
52. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 2001, 98(July (15)):8850-8855.
53. Solomon B. Immunological approaches as therapy for Alzheimer's disease. Expert Opin Biol Ther 2002, 2(December (8)):907-917.
54. Solomon B. Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease. DNA Cell Biol 2001, 20(November (11)):697-703.
55. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5(May (5)):452-457.
56. Mohajeri M.H., Saini K., Schultz J.G., Wollmer M.A., Hock C., Nitsch R.M. Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002, 277(September (36)):33012-33017.
57. Hock C., Konietzko U., Streffer J.R., Tracy J., Signorell A., Muller-Tillmanns B., et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003, 38(May (4)):547-554.
58. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298(November (5597)):1379.
59. Boche D., Denham N., Holmes C., Nicoll J.A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 2010, 120(September (3)):369-384.
60. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003, 9(April (4)):448-452.
61. Uro-Coste E., Russano de Paiva G., Guilbeau-Frugier C., Sastre N., Ousset P.J., da Silva N.A., et al. Cerebral amyloid angiopathy and microhemorrhages after amyloid beta vaccination: case report and brief review. Clin Neuropathol 2010, 29(July-August (4)):209-216.
62. Lee E.B., Leng L.Z., Lee V.M., Trojanowski J.Q. Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett 2005, 579(May (12)):2564-2568.
63. Morgan D. Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. Neurochem Int 2006, 49(July (2)):190-194.
64. Minami S.S., Sidahmed E., Aid S., Shimoji M., Niikura T., Mocchetti I., et al. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Abeta/amyloid burden in a transgenic mouse model of Alzheimer's disease. J Neuroinflamm 2010, 7:57.
65. Chauhan N.B., Siegel G.J. Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular antiamyloid beta antibody. J Neurosci Res 2002, 69(July (1)):10-23.
66. Chauhan N.B., Siegel G.J. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res 2003, 74(October (1)):142-147.
67. Chauhan N.B., Siegel G.J., Lichtor T. Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice. J Neurosci Res 2004, 78(December (5)):732-741.
68. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., et al. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 2001, 7(March (3)):369-372.
69. Solomon B. Towards Alzheimer's disease vaccination. Mini Rev Med Chem 2002, 2(February (1)):85-92.
70. Solomon B. Generation of anti-beta-amyloid antibodies via phage display technology towards Alzheimer's disease vaccination. Vaccine 2005, 23(March (17-18)):2327-2330.
71. Solomon B. Alzheimer's disease immunotherapy: from in vitro amyloid immunomodulation to in vivo vaccination. J Alzheimers Dis 2006, 9(Suppl. 3):433-438.
72. Chauhan N.B., Siegel G.J. Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. Neurosci Lett 2005, 375(March (3)):143-147.
73. Chauhan N.B. Intracerebroventricular passive immunization with anti-oligoAbeta antibody in TgCRND8. J Neurosci Res 2007, 85(February (2)):451-463.